Daiichi Sankyo awarded a Japan Science and Technology Agency “Newly extended Technology transfer Program” Grant

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that a R&D project for a novel, versatile vaccine adjuvant (hereafter, development project) for the purpose of creating a novel vaccine has been awarded a “Newly extended Technology transfer Program” (hereafter, NexTEP) grant from the Japan Science and Technology Agency (hereafter JST) and development on the project started from June 1.

By utilizing this grant, Daiichi Sankyo will promote the development of a novel, versatile vaccine adjuvant to realize the practical application of the research moving forward aligned with the National Institute of Biomedical Innovation (hereafter, NIBIO; Adjuvant project leader, Ken J. Ishii) and the University of Kitakyushu (hereafter, UKK; Professor Kazuo Sakurai, Faculty of Environmental Engineering), whereby all three organizations (Daiichi Sankyo, NIBIO, and UKK) have the necessary research seeds for this development program.

Daiichi Sankyo, NIBIO, and UKK contribute to the protection and improvement of people’s health and hygiene and the enhancement and dissemination of preventive medicine in Japan by supplying vaccines that meet unmet medical needs.